INVEST IN PHORMED TODAY!
Current first-line treatment options have severe side-effects and can be toxic; our technology targets the disease not just the symptoms
Exciting technology with the potential to treat multiple diseases means expanding opportunities for new markets and the potential for growth
The combined potential market is $8B+ per year
Patients suffering from Acute Myeloid Leukemia (AML), Hodgkin’s Lymphoma (HL), Parkinson’s disease (PD), and COVID-19 are faced with either the reality of no realistic treatment options or for some diseases like cancer, potentially harmful and painful treatments with long-lasting side-effects.
We are in the midst of clinical trials with our proprietary drug that will potentially be able to treat patients diagnosed with AML, HL, PD, COVID-19 and other projected diseases. Our technology, RP-323 works to “repair” the damaged cellular processes at the molecular level.
The world market for drugs treating HL is projected to post a compound annual growth rate (CAGR) of 16% over the next four years. The same projections expect the market to reach $1.4B by 2024.
The CAGR of the AML market is expected to be around 14% over the next five years, and is expected to top $1.5B by 2024.
The PD therapeutics world market was valued at over $2B in 2016 and is expected to rise with a CAGR of 10.9% from 2017 to 2025.
Combined, the total annual market for three of our drug’s potential uses could reach close to $8B by 2025.
The COVID-19 market is still to be determined.
The Safety Study has been completed establishing the validity and effectiveness of our drug. We are allocating Research & Development funds and are actively proceeding with next steps and clinical trials for all indications.
Our goal is to complete Phase II in all of our clinical trials.
RP-323 utilizes gene repair therapy to target damaged or mutated cells and repair a broad range of cell types. Our technology focuses on the root cause, aiming to fix the cellular damage on a molecular level.
The drug will be administered through intravenous infusion (I.V drip), as an out-patient treatment, unless otherwise suggested by the physician.
PhorMed will be open to a variety of exit strategies including but not limited to a go-public transaction, partnering with a Pharmaceutical or Biotech company through a distribution deal, or through a merger or acquisition.
All options will be considered based on the best outcome for our investors and the company, and the timing of these potential options is yet to be determined.
Current treatment options for some diseases have long-lasting and potentially devastating side effects because those treatments can damage or kill healthy cells.
Treatment recipients are not required to remain in the hospital thanks to the limited side effects and unobtrusive nature of the drug. We believe our treatment will be a safer, non-toxic alternative for a variety of applications including cancer, viruses and neurological disorders.
Phase II Clinical Trials are targeted for completion in the next 2.5 years. During the same period, the goal is to complete multiple licensing deals with pharmaceutical and/or biotech companies. We believe these major steps would precipitate expansion of our pipeline and the potential placement of multiple products in the marketplace.
We anticipate that in the next 3-4 years our company will be able to take advantage of the growing market and help fulfill unmet medical needs.
We have an opportunity to forever change the options facing patients suffering from these awful diseases. With treatment from our drug, we believe these patients will be able to take back their lives, and won’t be saddled with long-lasting side effects, or be required to live in the hospital for weeks on end.
The company anticipates a clear path toward an open and ever-growing marketplace. Through potential partnerships and a number of other possible exit strategies, we are confident in our ability to fulfill the market's need for new and safe treatment options.
THE OFFERING MATERIALS MAY CONTAIN FORWARD-LOOKING STATEMENTS AND INFORMATION RELATING TO, AMONG OTHER THINGS, THE COMPANY, ITS BUSINESS PLAN AND STRATEGY, AND ITS INDUSTRY. THESE FORWARD-LOOKING STATEMENTS ARE BASED ON THE BELIEFS OF, ASSUMPTIONS MADE BY, AND INFORMATION CURRENTLY AVAILABLE TO THE COMPANY’S MANAGEMENT. WHEN USED IN THE OFFERING MATERIALS, THE WORDS “ESTIMATE,” “PROJECT,” “BELIEVE,” “ANTICIPATE,” “INTEND,” “EXPECT” AND SIMILAR EXPRESSIONS ARE INTENDED TO IDENTIFY FORWARD-LOOKING STATEMENTS, WHICH CONSTITUTE FORWARD-LOOKING STATEMENTS. THESE STATEMENTS REFLECT MANAGEMENT’S CURRENT VIEWS WITH RESPECT TO FUTURE EVENTS AND ARE SUBJECT TO RISKS AND UNCERTAINTIES THAT COULD CAUSE THE COMPANY’S ACTUAL RESULTS TO DIFFER MATERIALLY FROM THOSE CONTAINED IN THE FORWARD-LOOKING STATEMENTS. INVESTORS ARE CAUTIONED NOT TO PLACE UNDUE RELIANCE ON THESE FORWARD-LOOKING STATEMENTS, WHICH SPEAK ONLY AS OF THE DATE ON WHICH THEY ARE MADE. THE COMPANY DOES NOT UNDERTAKE ANY OBLIGATION TO REVISE OR UPDATE THESE FORWARD-LOOKING STATEMENTS TO REFLECT EVENTS OR CIRCUMSTANCES AFTER SUCH DATE OR TO REFLECT THE OCCURRENCE OF UNANTICIPATED EVENTS.
PhorMed is a biopharmaceutical company leading the charge in the field of genomic medicine. We are working to utilize gene therapy to treat diseases, allowing the body to heal, and give new hope to patients suffering from diseases like AML, Hodgkin’s Lymphoma, Parkinson’s disease, and viruses.
Prof. Richard L. Chang
Inventor and CSO
Inventor and holder of multiple patents
124 peer-reviewed journal publications
Professor Chang has filed multiple significant patents for the treatment of cancer, infectious disease, hematology, and neurological disorders. Prof. Chang has over 53 years of research experience with such companies as Hoffman-La-Roche, Schering Corp, and Burroughs Wellcome and is a full professor and director of Research at Rutgers University. He successfully launched and completed off IND and IND phase I trials in China and US.
Holder of 2 scientific patents
Mr. Chang has previously been founder, director, CEO, President, CFO, and/or COO of such biotech companies as Biosuccess Biotech Co. LTD., Rich Pharmaceuticals, Inc., and HypGen, Inc. Mr. Chang started his life-science career as the founder and managing partner of Sun-Rich Chemicals, product development and distribution organization for nutraceuticals. Mr. Chang also has experience in international banking, venture capital, M&A, finance, go-public transactions, and organizational design and operations. Mr. Chang has a Bachelor of Science Degree in Economics from East Carolina University where he focused on accounting and international business.
Sean M. O’Connell, Ph.D.
65+ peer reviewed publications
Spearheading Parkinson’s disease study design
Early development stage collaboration with Prof. Richard Chang
Dr. O'Connell has served as CSO, CMO, Chief Scientist, SVP, and Founder of multiple pharmaceutical and research companies such as Novartis Pharmaceuticals, Vertical Spine, LLC., Cascade Medical Enterprises, and Integrated Communications Corp. (ICC/IPG). He has received numerous research grants and currently holds the position of Adjunct Professor in the Department of Vascular Surgery, Englewood Hospital and Medical Center, Mount Sinai School of Medicine, New York. He received his PhD in immunology and molecular biology from Rutgers University and the University of Medicine and Dentistry of New Jersey at New Brunswick (now Rutgers Medical school).
VP of Marketing & Business Development
Directly responsible for Marketing development
Mr. Greene’s experience includes direct B2B sales, Enterprise Software Sales, Business Development and Marketing, as well as IBM Power Systems Sales and management of server and cloud services teams. He has extensive experience in C-Level Business Development and the creation and editing of direct marketing content and campaigns. Mr. Greene has a Bachelor of Arts degree in Communications from Muhlenberg College.
Steven J. Davis
Extensive knowledge of Business, Corporate law
Mr. Davis’ experience ranges from serving on the Board of Directors of Philter Labs, Inc., and on the Board of Directors and Audit, Compensation and Nominating Committees of Telanetix, Inc. Prior to starting his own practice, Mr. Davis served as General Counsel and an executive officer of Molecular Imaging Corporation, and as in-house counsel for Leap Wireless International, Inc. He also practiced in the Business and Corporate Group in the San Diego office of Luce, Forward, Hamilton & Scripps LLP (now Dentons), a full-service law firm with over 200 attorneys, where he advised both private and public clients. Mr. Davis is licensed to practice law in California, the District of Columbia, and Minnesota. He received his Juris Doctor, Cum Laude, from the University of San Diego, School of Law in 1992. He received his B.A. in Political Science, Cum Laude, from Arizona State University in 1988.
McCoy Moretz M.D.
Maximum Number of Shares Offered subject to adjustment for bonus shares
1999 Avenue of the Stars, #1100, Century City, CA 90067
Minimum Investment Amount
Minimum Number of Shares Offered
Maximum Number of Shares Offered
Price per Share
*Maximum Number of Shares Offered subject to adjustment for bonus shares. See Bonus info below.
Volume Based Bonuses and Perks*:
*Investors cannot qualify for both bonuses in any single investment. If an investor qualifies for two bonuses the higher of the two bonuses will be applied. All perks occur after the offering is completed.
**Travel Not Included
Phormed Inc will offer 10% additional bonus shares for all investments that are committed by StartEngine Crowdfunding Inc. shareholders who invested over $1,000 or made at least two investments in StartEngine's own offerings.
This means eligible StartEngine shareholders will receive a 10% bonus for any shares they purchase in this offering. For example, if you buy 100 shares of Common Stock at $1.00 / share, you will receive 110 Common Stock shares, meaning you'll own 110 shares for $100. Fractional shares will not be distributed and share bonuses will be determined by rounding down to the nearest whole share.
This 10% Bonus is only valid during the investors eligibility period. Investors eligible for this bonus will also have priority if they are on a waitlist to invest and the company surpasses its maximum funding goal. They will have the first opportunity to invest should room in the offering become available if prior investments are cancelled or fail.
Investors will only receive a single bonus, which will be the highest bonus rate they are eligible for.
Irregular Use of Proceeds
The Company might incur Irregular Use of Proceeds that may include but are not limited to the following over $10,000: Vendor payments.
We are excited to announce, for the first time, results from our on-going preclinical studies of Acute Respiratory Distress Syndrome (ARDS). We have determined our drug RP-323 has the ability to limit inflammation associated with ARDS taking effect within 24 hours of administration.
ARDS can develop from numerous respiratory conditions including COVID-19 and there are currently no FDA approved targeted therapies for active ARDS. Patients have the potential to rapidly develop a variety of lung inflammatory conditions including general bronchial damage, fibrosis, vascular thrombosis, double pneumonia, and in severe cases, ARDS can lead to death.
We look forward to providing more data as it becomes available. We thank you for taking an active role by investing today and becoming part of the PhorMed family.
We have raised more than $125,000 today and over $250,000 since last Friday thanks to our 4,000+ investors.
Help us reach the $2.5 million milestone for this campaign.
Invest in these final 6 hours before our campaign ends and be part of our exciting new Gene Repair Technology.
Many thanks to all who have helped us raise $100,000 so far today.
We have also reached a milestone of more than 4,000 overall investors.
Help us close the day strong and join the PhorMed family by investing in our exciting Gene Repair Therapy.
Over $60,000 raised in the last hour.
Help keep the momentum by investing and help make our Gene Repair Therapy a reality for those who need it.
Nearly $24,000 raised yesterday.
Help beat yesterday's total and get us closer to our goal of Phase II human clinical trials.
Over $105,000 raised since Friday. Continue to help us push towards our goal of Phase II human trials. Invest and become part of the PhorMed family.
StartEngine Owner’s Bonus
This offering is eligible for the StartEngine Owner’s 10% Bonus program. For details on this program, please see the Offering Summary section below.
5% Bonus Shares
Invest $500+ and receive 5% bonus shares & access to our Investor Club which allows you to vote on drug names, receive special investor updates, and attend Q&A sessions
10% Bonus Shares
Invest $1,500+ and receive 10% bonus shares & access to our Investor Club.
15% Bonus Shares
Invest $5,000+ and receive 15% bonus shares & access to our Investor Club.
20% Bonus Shares
Invest $10,000+ and receive 20% bonus shares, an in-person meeting with the leadership team**, and access to our Investor Club.
Cancel anytime before 48 hours before a rolling close or the offering end date.
We want you to succeed and get the most out of your money by offering rewards and memberships!
Your info is your info. We take pride in keeping it that way!
Invest in over 200 start-ups and collectibles!
With Regulation A+, a non-accredited investor can only invest a maximum of 10% of their annual income or 10% of their net worth per year, whichever is greater. There are no restrictions for accredited investors.
With Regulation Crowdfunding, non-accredited investors with an annual income or net worth less than $124,000, are limited to invest a maximum of 5% of the greater of those two amounts. For those with an annual income and net worth greater than $124,000, he/she is limited to investing 10% of the greater of the two amounts.
At the close of an offering, all investors whose funds have “cleared” by this time will be included in the disbursement. At this time, each investor will receive an email from StartEngine with their Countersigned Subscription Agreement, which will serve as their proof of purchase moving forward.
Please keep in mind that a company can conduct a series of “closes” or withdrawals of funds throughout the duration of the campaign. If you are included in that withdrawal period, you will be emailed your countersigned subscription agreement and proof of purchase immediately following that withdrawal.
StartEngine assists companies in raising capital, and once the offering is closed, we are no longer involved with whether the company chooses to list shares on a secondary market, or what occurs thereafter. Therefore, StartEngine has no control or insight into your investment after the close of the live offering. In addition, we are not permitted to provide financial advice. You may want to contact a financial professional to discuss possible investment outcomes.
For Regulation Crowdfunding, investors are able to cancel their investment at any point throughout the campaign up until 48 hours before the closing of the offering. Note: If the company does a rolling close, they will post an update to their current investors, giving them the opportunity to cancel during this timeframe. If you do not cancel within this 5-day timeframe, your funds will be invested in the company, and you will no longer be able to cancel the investment. If your funds show as ‘Invested’ on your account dashboard, your investment can no longer be canceled.
For Regulation A+, StartEngine allows for a four-hour cancelation period. Once the four-hour window has passed, it is up to each company to set their own cancelation policy. You may find the company’s cancelation policy in the company’s offering circular.
Once your investment is canceled, there is a 10-day clearing period (from the date your investment was submitted). After your funds have cleared the bank, you will receive your refund within 10 business days.
Refunds that are made through ACH payments can take up to 10 business days to clear. Unfortunately, we are at the mercy of the bank, but we will do everything we can to get you your refund as soon as possible. However, every investment needs to go through the clearing process in order to get sent back to the account associated with the investment.
Both Title III (Regulation Crowdfunding) and Title IV (Reg A+) help entrepreneurs crowdfund capital investments from unaccredited and accredited investors. The differences between these regulations are related to the investor limitations, the differing amounts of money companies are permitted to raise, and differing disclosure and filing requirements. To learn more about Regulation Crowdfunding, click here, and for Regulation A+, click here.